文献速递瘢痕与激光

含高选择性生长因子的硅酮瘢痕膏安全性与疗效:双盲随机多中心研究

Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors Within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study.
PubMed 文献 · Aesthet Surg J · 2019-01-01

本研究比较了含选择性合成重组人生长因子和透明质酸的硅酮基质瘢痕膏SKN2017B与普通硅酮膏对成人术后瘢痕的疗效与安全性。

要点

  • SKN2017B在12周时研究者评估总体改善率74%,硅酮组54%,相对改善73%(P<0.0001)。
  • 患者评估SKN2017B组85%中度至显著改善,硅酮组51%,相对改善67%(P<0.001)。
  • 独立评审认为SKN2017B组87%瘢痕总体更优,硅酮组仅1%(P<0.0001),无耐受性问题。

核心结论

  • SKN2017B由高选择性生长因子与硅酮基质组成,耐受性好且对术后瘢痕管理有效。

主要发现

  • 治疗12周时,研究者评估SKN2017B组74%瘢痕总体改善,硅酮组54%,相对改善73%(P<0.0001)。
  • 患者评估SKN2017B组85%瘢痕中度至显著改善,硅酮组51%,相对改善67%(P<0.001)。
  • 独立评审者认为SKN2017B组87%瘢痕总体更优,硅酮组仅1%(P<0.0001)。
  • 两种膏剂均未出现耐受性问题或不良反应。

临床怎么用

  • 对于成人术后面部或躯干瘢痕,可考虑使用含选择性生长因子和透明质酸的硅酮基质瘢痕膏SKN2017B以改善瘢痕特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several growth factors and hyaluronic acid are implicated in fetal scarless healing. Whether these factors can be applied to an adult scar to improve scar characteristics is unknown. OBJECTIVES: This study compared the efficacy and safety of SKN2017B, a proprietary topical cream consisting of selective synthetic recombinant human growth factors and hyaluronic acid in a silicone base containing a specifically formulated silicone cream for postsurgical scar treatment. METHODS: In this prospective, randomized, controlled, double-blinded study, unilateral or bilateral facial or truncal scars in adult surgical patients were randomly treated with SKN2017B or silicone cream. Study investigators, study patients, and 2 independent reviewers assessed improvement in scar characteristics after 4 and 12 weeks of treatment. RESULTS: Forty-nine bilateral and 12 unilateral scars in 45 patients were treated with SKN2017B or silicone. At 12 weeks, investigators rated 74% of scars treated with SKN2017B as showing overall improvement vs 54% of silicone-treated scars, a 73% relative improvement with SKN2017B (P < 0.0001). Patients rated a moderate-to-significant improvement in 85% of SKN2017B-treated scars vs 51% of silicone-treated scars, a 67% relative improvement with SKN2017B (P < 0.001). Independent reviewers rated 87% of scars treated with SKN2017B to be better overall vs 1% of scars treated with silicone (P < 0.0001). There were no tolerability issues or adverse reactions with either cream. CONCLUSIONS: SKN2017B consists of highly selective growth factors within a silicone cream matrix and is well tolerated and effective for surgical scar management.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Zoumalan CI, Tadayon SC, Roostaeian J, et al. Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors Within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study. Aesthet Surg J. 2019. PMID: 30084900. doi:10.1093/asj/sjy185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。